共 50 条
- [1] Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder CancerJOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (26) : 3119 - +Massard, ChristopheGordon, Michael S.Sharma, SunilRafii, SaeedWainberg, Zev A.Luke, JasonCuriel, Tyler J.Colon-Otero, GerardoHamid, OmidSanborn, Rachel E.O'Donnell, Peter H.Drakaki, AlexandraTan, WinstonKurland, John F.Rebelatto, Marlon C.Jin, XiaopingBlake-Haskins, John A.Gupta, AshokSegal, Neil H.
- [2] Safety and clinical activity of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC)CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)Antonia, ScottRizvi, NaiyerBrahmer, JulieOu, Sai-HongKhleif, Samir N.Hwu, Wen-JenGutierrez, MartinSchoffski, PatrickHamid, OmidWeiss, JaredLutzky, JoseMaio, MicheleNemunaitis, JohnJaeger, DirkBalmanoukian, AniRebelatto, Marlon C.Steele, Keith E.Jin, XiaopingRobbins, Paul B.Blake-Haskins, John A.Segal, Neil H.
- [3] Safety and efficacy of durvalumab (MEDI4736) a PD-L1 antibody, in urothelial bladder cancer.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Massard, ChristopheGordon, Michael S.Sharma, SunilRafii, SaeedWainberg, Zev A.Luke, Jason JohnCuriel, Tyler J.Colon-Otero, GerardoHamid, OmidSanborn, Rachel E.O'Donnell, Peter H.Drakaki, AlexandraKurland, JohnRebelatto, Marlon C.Jin, XiaopingBlake-Haskins, John A.Gupta, Ashok KumarSegal, Neil Howard
- [4] Phase I study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in Japanese patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Iguchi, HaruoNogami, NaoyukiKozuki, ToshiyukiMatsumoto, ToshihikoTamura, KenjiYamamoto, NoboruShimomura, AkihikoHoshino, YujiMichibata, YoshikoNii, MasahiroFujiwara, Yutaka
- [5] A phase II study of the anti-programmed death ligand-1 antibody durvalumab (D; MEDI4736) in combination with PARP inhibitor, olaparib (O), in metastatic castration-resistant prostate cancer (mCRPC).JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)Karzai, FatimaMadan, Ravi AmritOwens, HelenHankin, AmyCouvillon, AnnaHouston, Nicole D.
- [6] Phase I, open-label study of MEDI0680, an anti-programmed cell death-1 (PD-1) antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with advanced malignancies.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Hamid, OmidChow, Laura Quan ManTavakkoli, FatemehMarshall, ShannonGribbin, Matthew JosephKarakunnel, Joyson JosephGray, Jhanelle Elaine
- [8] Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC).JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Rizvi, Naiyer A.Brahmer, Julie R.Ou, Sai-Hong IgnatiusSegal, Neil HowardKhleif, SamirHwu, Wen-JenGutierrez, MartinSchoffski, PatrickHamid, OmidWeiss, JaredLutzky, JoseMaio, MicheleNemunaitis, John J.Jaeger, DirkBalmanoukian, Ani SarkisRebelatto, MarlonSteele, KeithLi, XiaBlake-Haskins, John A.Antonia, Scott Joseph
- [9] Population pharmacokinetics of MEDI4736, a fully human anti-programmed death ligand 1 (PD-L1) monoclonal antibody, in patients with advanced solid tumorsEUROPEAN JOURNAL OF CANCER, 2015, 51 : S28 - S28Song, X.Pak, M.Chavez, C.Liang, M.Lu, H.Blake-Haskins, J. A.Robbins, P. B.Jin, X.Gupta, A.Roskos, L.Narwal, R.